What is Bicycle Therapeutics Limited's earnings per share (EPS)?

Bicycle Therapeutics Limited (BCYC) reported diluted earnings per share of $-3.16 for fiscal year 2025. This represents a -9.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bicycle Therapeutics Limited Financials

BCYC

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Bicycle Therapeutics Limited (BCYC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCYC FY2025 2026-04-30

BCYC remains an equity-funded R&D business, with revenue growth still overwhelmed by a much larger cash-burn engine.

From FY2024 to FY2025, revenue rose to $72.6M while operating cash outflow widened to -$249.7M, so higher sales did not improve the model’s cash economics. The reason is visible in spending: R&D reached $240.3M in FY2025 after $173.0M in FY2024, keeping the business governed by research intensity rather than commercial scale.

The balance sheet is cash-rich but externally funded: cash ended FY2025 at $628.1M against only $107.6M of total liabilities. That cushion was built by prior financing, especially the $519.8M inflow in FY2024, which means the operating model has been financed primarily with shareholder capital rather than debt or self-generated cash.

Capex was just $2.4M in FY2025, which is why free cash flow stayed close to operating cash flow at -$252.0M. In practice, this is an asset-light cash burn: the company is consuming cash through ongoing operations and research, not through factories, inventory, or other heavy fixed-asset build-out.

Financial Health Signals

Financial Health Score 63/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bicycle Therapeutics Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-0.03

Bicycle Therapeutics Limited scores -0.03, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($307.9M) relative to total liabilities ($107.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Bicycle Therapeutics Limited passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

1.14x

For every $1 of reported earnings, Bicycle Therapeutics Limited generates $1.14 in operating cash flow (-$249.7M OCF vs -$219.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1199.3x

Bicycle Therapeutics Limited earns $-1199.3 in operating income for every $1 of interest expense (-$247.1M vs $206K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$72.6M

YoY+105.8%

5Y CAGR+47.5%

Bicycle Therapeutics Limited generated $72.6M in revenue in fiscal year 2025. This represents an increase of 105.8% from the prior year.

EBITDA

-$240.6M

YoY-18.7%

Bicycle Therapeutics Limited's EBITDA was -$240.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.7% from the prior year.

Net Income

-$219.0M

YoY-29.5%

Bicycle Therapeutics Limited reported -$219.0M in net income in fiscal year 2025. This represents a decrease of 29.5% from the prior year.

EPS (Diluted)

$-3.16

YoY-9.0%

Bicycle Therapeutics Limited earned $-3.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 9.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$252.0M

YoY-51.9%

Bicycle Therapeutics Limited generated -$252.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 51.9% from the prior year.

Cash & Debt

$628.1M

YoY-28.6%

Bicycle Therapeutics Limited held $628.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Bicycle Therapeutics Limited paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

69M

YoY+0.4%

5Y CAGR+26.9%

Bicycle Therapeutics Limited had 69M shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-340.4%

YoY+254.6pp

5Y CAGR+159.7pp

Bicycle Therapeutics Limited's operating margin was -340.4% in fiscal year 2025, reflecting core business profitability. This is up 254.6 percentage points from the prior year.

Net Margin

-301.7%

YoY+177.5pp

5Y CAGR+189.3pp

Bicycle Therapeutics Limited's net profit margin was -301.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 177.5 percentage points from the prior year.

Return on Equity

-35.9%

YoY-14.6pp

5Y CAGR+17.5pp

Bicycle Therapeutics Limited's ROE was -35.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 14.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$240.3M

YoY+38.9%

5Y CAGR+48.6%

Bicycle Therapeutics Limited invested $240.3M in research and development in fiscal year 2025. This represents an increase of 38.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.4M

YoY+90.3%

5Y CAGR+14.4%

Bicycle Therapeutics Limited invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 90.3% from the prior year.

BCYC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$72.6M+105.8%	$35.3M+30.8%	$27.0M+86.5%	$14.5M+23.6%	$11.7M+12.6%	$10.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$240.3M+38.9%	$173.0M+10.5%	$156.5M+91.8%	$81.6M+81.8%	$44.9M+35.4%	$33.1M
SG&A Expenses	$79.4M+10.0%	$72.2M+19.5%	$60.4M+22.1%	$49.5M+52.6%	$32.4M+11.1%	$29.2M
Operating Income	-$247.1M-17.7%	-$209.9M-10.5%	-$189.9M-62.8%	-$116.7M-77.8%	-$65.6M-26.3%	-$52.0M
Interest Expense	$206K-88.1%	$1.7M-47.0%	$3.3M-2.4%	$3.3M+12.1%	$3.0M+553.0%	$457K
Income Tax	$152K+103.2%	-$4.8M-427.0%	$1.5M+195.6%	-$1.5M+8.4%	-$1.7M-129.7%	-$724K
Net Income	-$219.0M-29.5%	-$169.0M+6.4%	-$180.7M-60.3%	-$112.7M-68.7%	-$66.8M-31.0%	-$51.0M
EPS (Diluted)	$-3.16-9.0%	$-2.90+42.9%	$-5.08-33.7%	$-3.80-42.3%	$-2.67-0.4%	$-2.66

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$887K-98.2%	$48.0M+308.7%	$11.7M+301.8%	$2.9M-70.7%	$10.0M+169.1%	$3.7M+38.6%	$2.7M-71.4%	$9.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$48.9M-5.5%	$51.8M-11.4%	$58.4M-17.7%	$71.0M+20.3%	$59.1M+18.6%	$49.8M+3.1%	$48.3M+20.5%	$40.1M
SG&A Expenses	$17.5M-16.4%	$20.9M+10.8%	$18.9M+2.0%	$18.5M-12.5%	$21.1M-2.2%	$21.6M+18.3%	$18.3M+14.5%	$15.9M
Operating Income	-$65.5M-165.0%	-$24.7M+62.3%	-$65.6M+24.3%	-$86.6M-23.4%	-$70.2M-3.8%	-$67.7M-6.0%	-$63.8M-36.9%	-$46.6M
Interest Expense	$48K-15.8%	$57K+29.5%	$44K-18.5%	$54K+5.9%	$51K-1.9%	$52K+57.6%	$33K-96.0%	$824K
Income Tax	$172K-86.4%	$1.3M+517.1%	$205K+188.7%	-$231K+78.7%	-$1.1M-0.5%	-$1.1M+68.6%	-$3.4M-3098.3%	$115K
Net Income	-$60.8M-201.8%	-$20.2M+65.9%	-$59.1M+25.1%	-$79.0M-30.0%	-$60.8M-17.2%	-$51.9M-2.1%	-$50.8M-27.6%	-$39.8M
EPS (Diluted)	$-0.87	N/A	$-0.85+25.4%	$-1.14-29.5%	$-0.88	N/A	$-0.74+3.9%	$-0.77

BCYC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$717.6M-25.0%	$956.9M+60.7%	$595.3M+45.0%	$410.6M-14.4%	$479.8M+197.7%	$161.2M
Current Assets	$682.9M-26.5%	$928.6M+65.3%	$561.9M+52.1%	$369.4M-19.4%	$458.6M+194.5%	$155.7M
Cash & Equivalents	$628.1M-28.6%	$879.5M+67.1%	$526.4M+55.2%	$339.2M-22.7%	$438.7M	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0	$0-100.0%	$2.0M+104.5%	$1.0M-81.7%	$5.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$107.6M-34.3%	$163.8M-27.0%	$224.4M+60.5%	$139.8M+4.7%	$133.5M+103.3%	$65.7M
Current Liabilities	$57.0M-15.2%	$67.2M-3.3%	$69.5M+30.4%	$53.3M+47.2%	$36.2M+56.7%	$23.1M
Long-Term Debt	N/A	N/A	$30.7M+1.3%	$30.3M+1.5%	$29.9M+105.9%	$14.5M
Total Equity	$610.0M-23.1%	$793.1M+113.8%	$370.9M+37.0%	$270.8M-21.8%	$346.3M+262.7%	$95.5M
Retained Earnings	-$899.8M-32.2%	-$680.8M-33.0%	-$511.8M-54.6%	-$331.1M-51.6%	-$218.4M-44.1%	-$151.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$652.4M-9.1%	$717.6M-6.1%	$764.0M-8.2%	$832.2M-5.9%	$883.9M-7.6%	$956.9M-4.0%	$996.7M-5.7%	$1.1B
Current Assets	$619.1M-9.3%	$682.9M-7.6%	$738.8M-8.1%	$804.3M-6.1%	$856.1M-7.8%	$928.6M-3.9%	$966.2M-6.0%	$1.0B
Cash & Equivalents	$559.5M-10.9%	$628.1M-3.1%	$648.3M-10.1%	$721.5M-9.0%	$793.0M-9.8%	$879.5M-1.3%	$890.9M-7.3%	$961.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$0	N/A	N/A	$136K	$0	N/A	$233K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$98.1M-8.9%	$107.6M-26.0%	$145.5M-10.9%	$163.3M+13.7%	$143.6M-12.4%	$163.8M-1.2%	$165.7M-9.7%	$183.5M
Current Liabilities	$48.9M-14.2%	$57.0M-17.8%	$69.3M-10.5%	$77.4M+34.4%	$57.6M-14.3%	$67.2M+19.2%	$56.4M-19.0%	$69.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$8.5M
Total Equity	$554.3M-9.1%	$610.0M-1.4%	$618.5M-7.5%	$668.9M-9.6%	$740.3M-6.6%	$793.1M-4.6%	$831.0M-4.9%	$873.8M
Retained Earnings	-$960.6M-6.8%	-$899.8M-2.3%	-$879.6M-7.2%	-$820.5M-10.6%	-$741.5M-8.9%	-$680.8M-8.2%	-$628.9M-8.8%	-$578.1M

BCYC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$249.7M-51.6%	-$164.7M-171.7%	-$60.6M+29.6%	-$86.1M-482.1%	-$14.8M+16.8%	-$17.8M
Capital Expenditures	$2.4M+90.3%	$1.2M-57.8%	$2.9M-84.6%	$19.0M+835.3%	$2.0M+69.2%	$1.2M
Free Cash Flow	-$252.0M-51.9%	-$166.0M-161.1%	-$63.6M+39.5%	-$105.1M-524.7%	-$16.8M+11.4%	-$19.0M
Investing Cash Flow	-$2.4M-90.3%	-$1.2M+57.8%	-$2.9M+84.6%	-$19.0M-835.3%	-$2.0M-69.2%	-$1.2M
Financing Cash Flow	-$131K-100.0%	$519.8M+107.9%	$250.0M+3636.2%	$6.7M-97.9%	$320.7M+410.4%	$62.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$65.9M-240.8%	-$19.3M+72.8%	-$71.2M+2.2%	-$72.8M+15.7%	-$86.4M-819.2%	-$9.4M+76.4%	-$39.8M+10.7%	-$44.6M
Capital Expenditures	$713K+24.2%	$574K-14.8%	$674K+35.3%	$498K-17.5%	$604K+64.1%	$368K-15.4%	$435K+3.6%	$420K
Free Cash Flow	-$66.6M-234.5%	-$19.9M+72.3%	-$71.8M+2.0%	-$73.3M+15.7%	-$87.0M-790.8%	-$9.8M+75.8%	-$40.3M+10.6%	-$45.0M
Investing Cash Flow	-$713K-24.2%	-$574K+14.8%	-$674K-35.3%	-$498K+17.5%	-$604K-64.1%	-$368K+15.4%	-$435K-3.6%	-$420K
Financing Cash Flow	-$54K-260.0%	-$15K+50.0%	-$30K+33.3%	-$45K-9.8%	-$41K-120.2%	$203K+100.6%	-$31.9M-105.8%	$549.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BCYC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-340.4%+254.6pp	-595.0%+109.2pp	-704.1%+102.4pp	-806.6%-245.6pp	-561.0%-60.9pp	-500.1%
Net Margin	-301.7%+177.5pp	-479.2%+190.5pp	-669.7%+109.6pp	-779.4%-208.1pp	-571.3%-80.3pp	-491.0%
Return on Equity	-35.9%-14.6pp	-21.3%+27.4pp	-48.7%-7.1pp	-41.6%-22.3pp	-19.3%+34.1pp	-53.4%
Return on Assets	-30.5%-12.8pp	-17.7%+12.7pp	-30.3%-2.9pp	-27.5%-13.5pp	-13.9%+17.7pp	-31.6%
Current Ratio	11.98-1.8	13.81+5.7	8.08+1.2	6.92-5.7	12.65+5.9	6.73
Debt-to-Equity	0.18-0.0	0.21+0.1	0.08-0.0	0.11+0.0	0.09-0.1	0.15
FCF Margin	-347.2%+123.3pp	-470.5%-234.9pp	-235.6%+491.1pp	-726.7%-582.8pp	-143.8%+38.9pp	-182.8%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7382.4%-7330.9pp	-51.5%+507.1pp	-558.6%+2407.2pp	-2965.8%-2262.2pp	-703.7%+1121.1pp	-1824.8%+561.1pp	-2385.9%-1887.6pp	-498.3%
Net Margin	-6857.4%-6815.4pp	-42.0%+461.6pp	-503.7%+2200.2pp	-2703.8%-2094.9pp	-608.9%+789.5pp	-1398.4%+500.0pp	-1898.4%-1473.1pp	-425.3%
Return on Equity	-11.0%-7.7pp	-3.3%+6.3pp	-9.6%+2.2pp	-11.8%-3.6pp	-8.2%-1.7pp	-6.5%-0.4pp	-6.1%-1.6pp	-4.6%
Return on Assets	-9.3%-6.5pp	-2.8%+4.9pp	-7.7%+1.8pp	-9.5%-2.6pp	-6.9%-1.4pp	-5.4%-0.3pp	-5.1%-1.3pp	-3.8%
Current Ratio	12.66+0.7	11.98+1.3	10.66+0.3	10.39-4.5	14.86+1.0	13.81-3.3	17.13+2.4	14.77
Debt-to-Equity	0.180.0	0.18-0.1	0.240.0	0.24+0.1	0.19-0.0	0.210.0	0.20+0.2	0.01
FCF Margin	-7512.7%-7471.2pp	-41.5%+570.8pp	-612.3%+1897.4pp	-2509.7%-1638.0pp	-871.7%-608.4pp	-263.3%+1241.4pp	-1504.8%-1023.5pp	-481.2%

Similar Companies

$2.0B

$922.6M

$524.8M

$53.4M

Arcturus Therape ARCT

$198.1M

Frequently Asked Questions

What is Bicycle Therapeutics Limited's annual revenue?

Bicycle Therapeutics Limited (BCYC) reported $72.6M in total revenue for fiscal year 2025. This represents a 105.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bicycle Therapeutics Limited's revenue growing?

Bicycle Therapeutics Limited (BCYC) revenue grew by 105.8% year-over-year, from $35.3M to $72.6M in fiscal year 2025.

Is Bicycle Therapeutics Limited profitable?

No, Bicycle Therapeutics Limited (BCYC) reported a net income of -$219.0M in fiscal year 2025, with a net profit margin of -301.7%.

What is Bicycle Therapeutics Limited's EBITDA?

Bicycle Therapeutics Limited (BCYC) had EBITDA of -$240.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bicycle Therapeutics Limited's operating margin?

Bicycle Therapeutics Limited (BCYC) had an operating margin of -340.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bicycle Therapeutics Limited's net profit margin?

Bicycle Therapeutics Limited (BCYC) had a net profit margin of -301.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bicycle Therapeutics Limited's return on equity (ROE)?

Bicycle Therapeutics Limited (BCYC) has a return on equity of -35.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bicycle Therapeutics Limited's free cash flow?

Bicycle Therapeutics Limited (BCYC) generated -$252.0M in free cash flow during fiscal year 2025. This represents a -51.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bicycle Therapeutics Limited's operating cash flow?

Bicycle Therapeutics Limited (BCYC) generated -$249.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bicycle Therapeutics Limited's total assets?

Bicycle Therapeutics Limited (BCYC) had $717.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bicycle Therapeutics Limited's capital expenditures?

Bicycle Therapeutics Limited (BCYC) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bicycle Therapeutics Limited spend on research and development?

Bicycle Therapeutics Limited (BCYC) invested $240.3M in research and development during fiscal year 2025.

How many shares does Bicycle Therapeutics Limited have outstanding?

Bicycle Therapeutics Limited (BCYC) had 69M shares outstanding as of fiscal year 2025.

What is Bicycle Therapeutics Limited's current ratio?

Bicycle Therapeutics Limited (BCYC) had a current ratio of 11.98 as of fiscal year 2025, which is generally considered healthy.

What is Bicycle Therapeutics Limited's debt-to-equity ratio?

Bicycle Therapeutics Limited (BCYC) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bicycle Therapeutics Limited's return on assets (ROA)?

Bicycle Therapeutics Limited (BCYC) had a return on assets of -30.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bicycle Therapeutics Limited's cash runway?

Based on fiscal year 2025 data, Bicycle Therapeutics Limited (BCYC) had $628.1M in cash against an annual operating cash burn of $249.7M. This gives an estimated cash runway of approximately 30 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bicycle Therapeutics Limited's Altman Z-Score?

Bicycle Therapeutics Limited (BCYC) has an Altman Z-Score of -0.03, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bicycle Therapeutics Limited's Piotroski F-Score?

Bicycle Therapeutics Limited (BCYC) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bicycle Therapeutics Limited's earnings high quality?

Bicycle Therapeutics Limited (BCYC) has an earnings quality ratio of 1.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bicycle Therapeutics Limited cover its interest payments?

Bicycle Therapeutics Limited (BCYC) has an interest coverage ratio of -1199.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bicycle Therapeutics Limited?

Bicycle Therapeutics Limited (BCYC) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.